Consensus AbbVie Inc. Thailand S.E.

Stocks

ABBV19

TH8483124005

Pharmaceuticals

End-of-day quote Thailand S.E. 02/11/2026			5-day change	1st Jan Change
9.900 ^THB	-1.98%		+2.06%	+35.62%

03/11	Galderma Finance Chief to Step Down, Months After Joining Company	DJ
03/11	Canaccord Genuity Adjusts Price Target on AbbVie to $338 From $290	MT

f7653b311728fd737de80.tJ_j_PRJnm9xFkHnl7CQdkBXs739z1rM49_LV-y82TY._KuZjKcn5CEdJxjRr8f0JTMS1e-xhDiDiaXzOqWElwfn5425gwWuPityeQ~6eee413364577d6bc4fcb30367550b6e

Analysts' recommendations: AbbVie Inc.

03/11	Canaccord Genuity Adjusts Price Target on AbbVie to $338 From $290	MT
03/11	Leerink Partners Adjusts Price Target on AbbVie to $325 From $279	MT
03/11	Goldman Sachs Adjusts Price Target on AbbVie to $313 From $294	MT
02/11	RBC Raises Price Target on AbbVie to $330 From $280, Keeps Outperform Rating	MT
02/11	Cantor Fitzgerald Adjusts Price Target on AbbVie to $325 From $290	MT
02/11	Guggenheim Adjusts Price Target on AbbVie to $322 From $288	MT
23/10	Avalo Therapeutics Abdakibart Potential Intact After AbbVie Data, Wedbush Says	MT
22/10	Goldman Sachs Adjusts Price Target on AbbVie to $294 From $258	MT
21/10	BofA: UCB's Bimzelx Sets 'Very High' Bar Ahead of Q4 Competitor Data in Hidradenitis Suppurativa	MT
21/10	Barclays Adjusts Price Target on AbbVie to $325 From $300	MT
21/10	Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says	MT
21/10	Global markets live: Google, Apple, Amazon, 3M, Waymo…
14/10	AbbVie Poised for Q3 Top-Line Beat Driven by Rinvoq, Skyrizi, and Vraylar Therapies, RBC Says	MT
10/10	UBS Adjusts Price Target on AbbVie to $275 From $260, Maintains Neutral Rating	MT
09/10	BofA Securities Adjusts AbbVie Price Target to $305 From $289	MT
08/10	Cantor Fitzgerald Adjusts Price Target on AbbVie to $290 From $285	MT
08/10	JPMorgan Adjusts Price Target on AbbVie to $300 From $285	MT
07/10	Morgan Stanley Adjusts Price Target on AbbVie to $310 From $296	MT
07/10	AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says	MT
07/10	Scotiabank Adjusts Price Target on AbbVie to $320 From $280, Maintains Sector Outperform Rating	MT
30/09	AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says	MT
29/09	BofA Securities Adjusts AbbVie Price Target to $289 From $282, Maintains Buy Rating	MT
25/09	Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says	MT
10/09	HSBC Adjusts Price Target on AbbVie to $315 From $300, Keeps Buy Rating	MT
08/09	BofA Securities Adjusts Price Target on AbbVie to $282 From $276	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+0.25%
	JOHNSON & JOHNSON					+2.27%
	ABBVIE INC.					+0.77%
	ROCHE HOLDING AG					-2.72%
	MERCK & CO., INC.					+6.95%
	NOVARTIS AG					-5.37%
	ASTRAZENECA PLC					+12.86%
	AMGEN INC.					-14.74%
	GILEAD SCIENCES, INC.					+1.07%
	Average					+0.15%
	Weighted average by Cap.					+0.54%